Though the mechanism remains unclear as to how PDE5 inhibition could result in a reduction in all‐cause death, these findings are significant because of the widespread use of PDE5 inhibitors for the treatment of ED, as well as common use in advanced pulmonary hypertension [24], and off‐label use in the management of high‐altitude pulmonary edema [25], Raynaud phenomenon [26], and colorectal cancer as adjuvant therapy [27]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.